Current Vascular Pharmacology · 2018 · 15 citations · 36 references
MedicineCardiologyInternal MedicineClinical CardiologyClinical EpidemiologyEpidemiologyAcute Coronary SyndromesCardiovascular DiseaseCardiovascular EpidemiologyCardiovascular RiskCoronary Artery DiseaseDiabetes MellitusAcute Coronary Syndrome Risk StratificationAdult PrevalenceDiabetes MortalityHigh-risk Population PrevalenceKaplan-meier Confidence IntervalsKaplan-meier Survival EstimatesNon-st-elevation Myocardial InfarctionStratified Kaplan-meier Estimation
BACKGROUND: The prevalence of traditional risk factors such as diabetes mellitus (DM) and obesity are increasing in patients with acute coronary syndrome (ACS). Furthermore, outcomes after ACS are worse in patients with DM. The high prevalence of DM and an early age at onset of ACS have been described in prior publications from the Gulf Coast Database. AIMS: We aimed to define the effect of DM on total mortality following ACS presentation at 30-days and 1 year based on the Gulf COAST registry database. METHODS: The Gulf COAST registry is a prospective, multinational, longitudinal, observational cohort study conducted among Gulf citizens admitted with a diagnosis of ACS. The outcomes among patients with DM following ACS were stratified into 2 groups based on their DM status. Cumulative survival stratified by groups and subgroup categories was assessed by the Kaplan-Meier method. RESULTS: Of 3,576 ACS patients, 2,730 (76.3%) presented with non ST-segment elevation myocardial infarction (NSTEMI) and 846 (23.6%) with STEMI. Overall, 1906 patients (53.3%) had DM. A significantly higher in-hospital (4.8%), 30-day (6.7%) and 1-year (13.7%) mortality were observed in patients with DM compared with those without DM. The Kaplan-Meier survival curve showed significant differences in survival of ACS patients with or without DM, with a short period of time-to-event for DM patients with STEMI (30-days) and the longest (1-year) for NSTEMI patients without DM. CONCLUSION: DM patients presenting with ACS-STEMI have poor short-term outcomes while DMNSTEMI patients have poor long-term outcomes. This highlights the need for strategies to evaluate DM control and integration of care to control vascular risk among this high-risk population.
36
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016 · 7.3K citations · Full text
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer, Brian Claggett, Rafael Díaz et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text
Medicine, Cardiology, Pharmacology +17
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Umesh N. Khot · JAMA · 2003 · 1.5K citations